Novo Nordisk A/S
NVO67.605USD
-0.635-0.93%
Trading geöffnet （ET）Kurse um 15 Minuten verzögert
227.56BMarktkapitalisierung
15.53KGV TTM
mehr Informationen über Novo Nordisk A/S Unternehmen
Novo Nordisk A/S is a global healthcare company engaged in diabetes care. The Company is also engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. The Company operates through two business segments: diabetes and obesity care, and biopharmaceuticals. The Company's diabetes and obesity care segment covers insulin, GLP-1, other protein-related products, such as glucagon, protein-related delivery systems and needles, and oral anti-diabetic drugs. The Company's biopharmaceuticals segment covers the therapy areas of hemophilia care, growth hormone therapy and hormone replacement therapy. The Company also offers Saxenda product to treat obesity. It offers a range of products, including NovoLog/NovoRapid; NovoLog Mix/NovoMix; Prandin/NovoNorm; NovoSeven; Norditropin, and Vagifem. As of December 31, 2016, it marketed its products in over 180 countries. Its regional structure consists of two commercial units: North America and International Operations.
Unternehmensinformationen
Unternehmens-codeNVO
Name des UnternehmensNovo Nordisk A/S
IPO-datumMay 17, 1974
Gegründet am1931
CEOMr. Lars Fruergaard Joergensen
Anzahl der mitarbeiter76302
WertpapierartOrdinary Share
GeschäftsjahresendeMay 17
AddresseNovo Alle 1
StadtBAGSVAERD
BörseThe Toronto Stock Exchange
LandDenmark
Postleitzahl2880
Telefon4544448888
Websitehttps://www.novonordisk.com/
Unternehmens-codeNVO
IPO-datumMay 17, 1974
Gegründet am1931
Führungskräfte
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Jacob Martin Wiborg Rode
Mr. Jacob Martin Wiborg Rode
Head of Investor Relations
Head of Investor Relations
--
--
Mr. Helge Lund
Mr. Helge Lund
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Mr. David Moore
Mr. David Moore
Executive Vice President - US Operations and Business Development
Executive Vice President - US Operations and Business Development
--
--
Mr. Karsten Munk Knudsen
Mr. Karsten Munk Knudsen
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
--
--
Ms. Camilla Sylvest
Ms. Camilla Sylvest
Executive Vice President - Commercial Strategy and Corporate Affairs
Executive Vice President - Commercial Strategy and Corporate Affairs
--
--
Mr. Thomas Rantzau
Mr. Thomas Rantzau
Director, Employee Representative
Director, Employee Representative
--
--
Ms. Tania Sabroe
Ms. Tania Sabroe
Executive Vice President - Global People and Organisation
Executive Vice President - Global People and Organisation
--
--
Dr. Martin Holst Lange
Dr. Martin Holst Lange
Executive Vice President - Development
Executive Vice President - Development
--
--
Mr. Andreas Fibig
Mr. Andreas Fibig
Independent Director
Independent Director
--
--
Dr. Sylvie L. Gregoire, Pharm.D.
Dr. Sylvie L. Gregoire, Pharm.D.
Independent Director
Independent Director
--
--
Mehr Anzeigen
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Jacob Martin Wiborg Rode
Mr. Jacob Martin Wiborg Rode
Head of Investor Relations
Head of Investor Relations
--
--
Mr. Helge Lund
Mr. Helge Lund
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Mr. David Moore
Mr. David Moore
Executive Vice President - US Operations and Business Development
Executive Vice President - US Operations and Business Development
--
--
Mr. Karsten Munk Knudsen
Mr. Karsten Munk Knudsen
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
--
--
Ms. Camilla Sylvest
Ms. Camilla Sylvest
Executive Vice President - Commercial Strategy and Corporate Affairs
Executive Vice President - Commercial Strategy and Corporate Affairs
--
--
Mr. Thomas Rantzau
Mr. Thomas Rantzau
Director, Employee Representative
Director, Employee Representative
--
--
Umsatzaufteilung
Währung: USDUpdate-Zeit: 22 hours ago
Währung: USDUpdate-Zeit: 22 hours ago
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2021
FY2020
FY2019
Nach GeschäftsbereichUSD
Name
Umsatz
Anteil
Total GLP-1
21.63B
51.35%
Obesity (Saxenda®)
9.45B
22.43%
Long-acting insulin
2.77B
6.58%
Fast-acting insulin
2.69B
6.38%
Rare blood disorders
1.76B
4.18%
Other
3.83B
9.08%
Nach RegionUSD
Name
Umsatz
Anteil
USA
24.28B
57.64%
EMEA
8.76B
20.80%
Rest of World
4.83B
11.48%
Region China
2.68B
6.37%
Canada
1.56B
3.71%
Nach Geschäftsbereich
Nach Region
Nach GeschäftsbereichUSD
Name
Umsatz
Anteil
Total GLP-1
21.63B
51.35%
Obesity (Saxenda®)
9.45B
22.43%
Long-acting insulin
2.77B
6.58%
Fast-acting insulin
2.69B
6.38%
Rare blood disorders
1.76B
4.18%
Other
3.83B
9.08%
Aktionäre
Update-Zeit: Tue, Mar 11
Update-Zeit: Tue, Mar 11
Aktionärsstatistik
Art
Aktionärsstatistik
Aktionäre
Anteil
Jennison Associates LLC
0.59%
GQG Partners, LLC
0.39%
Fisher Investments
0.38%
Loomis, Sayles & Company, L.P.
0.34%
Fayez Sarofim & Co.
0.34%
Other
97.96%
Aktionärsstatistik
Aktionäre
Anteil
Jennison Associates LLC
0.59%
GQG Partners, LLC
0.39%
Fisher Investments
0.38%
Loomis, Sayles & Company, L.P.
0.34%
Fayez Sarofim & Co.
0.34%
Other
97.96%
Art
Aktionäre
Anteil
Investment Advisor
5.20%
Investment Advisor/Hedge Fund
2.91%
Research Firm
0.82%
Hedge Fund
0.64%
Pension Fund
0.28%
Insurance Company
0.21%
Bank and Trust
0.17%
Family Office
0.02%
Family Office
0.02%
Other
89.73%
Institutionelle Beteiligung
Update-Zeit: Thu, Feb 20
Update-Zeit: Thu, Feb 20
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2025Q1
2661
349.97M
10.40%
+3.00M
2024Q4
2676
348.53M
10.35%
+330.19K
2024Q3
2529
339.29M
10.15%
-6.04M
2024Q2
2456
341.24M
10.21%
+6.87M
2024Q1
2291
330.25M
9.75%
+10.89M
2023Q4
2037
314.57M
9.30%
+1.47M
2023Q3
1826
307.14M
8.91%
+4.22M
2023Q2
1692
293.83M
8.50%
+768.69K
2023Q1
1603
284.38M
8.30%
-15.92M
2022Q4
1498
293.73M
8.57%
+2.21M
Mehr Anzeigen
Aktionärsaktivitäten
Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
Jennison Associates LLC
19.94M
0.59%
-251.15K
-1.24%
Dec 31, 2024
GQG Partners, LLC
12.99M
0.39%
+5.56M
+74.70%
Dec 31, 2024
Fisher Investments
12.64M
0.38%
-664.99K
-5.00%
Dec 31, 2024
Loomis, Sayles & Company, L.P.
11.57M
0.34%
+2.95M
+34.18%
Dec 31, 2024
Fayez Sarofim & Co.
11.38M
0.34%
-832.64K
-6.82%
Dec 31, 2024
Fidelity Management & Research Company LLC
9.89M
0.29%
-7.78M
-44.05%
Dec 31, 2024
Managed Account Advisors LLC
9.39M
0.28%
+1.11M
+13.43%
Dec 31, 2024
Folketrygdfondet
8.90M
0.26%
+40.31K
+0.45%
Dec 31, 2024
Renaissance Technologies LLC
8.31M
0.25%
+123.68K
+1.51%
Dec 31, 2024
Capital International Investors
6.75M
0.2%
-204.59K
-2.94%
Dec 31, 2024
Mehr Anzeigen
Verbundene ETFs
Update-Zeit: Wed, Apr 2
Update-Zeit: Wed, Apr 2
Name
Anteil
Novo Nordisk A/S (B Shares) ADRhedged
100%
Roundhill GLP-1 & Weight Loss ETF
15.18%
Amplify Weight Loss Drug & Treatment ETF
13.08%
VanEck Pharmaceutical ETF
6.51%
iShares Long-Term US Equity Active ETF
4.59%
AdvisorShares Gerber Kawasaki ETF
4.03%
TrueShares Technology, AI & Deep Learning ETF
3.12%
Clockwise Core Equity & Innovation ETF
2.63%
PGIM Jennison Better Future ETF
2.37%
SP Funds S&P World (ex-US) ETF
2.34%
Mehr Anzeigen
Novo Nordisk A/S (B Shares) ADRhedged
Anteil100%
Roundhill GLP-1 & Weight Loss ETF
Anteil15.18%
Amplify Weight Loss Drug & Treatment ETF
Anteil13.08%
VanEck Pharmaceutical ETF
Anteil6.51%
iShares Long-Term US Equity Active ETF
Anteil4.59%
AdvisorShares Gerber Kawasaki ETF
Anteil4.03%
TrueShares Technology, AI & Deep Learning ETF
Anteil3.12%
Clockwise Core Equity & Innovation ETF
Anteil2.63%
PGIM Jennison Better Future ETF
Anteil2.37%
SP Funds S&P World (ex-US) ETF
Anteil2.34%
Dividende
In den vergangenen 5 Jahren wurden insgesamt
21.09B
USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Aug 06, 2024
NVO.NB Final Cash Dividend of gross USD 0.516902 paid on Aug 26, 2024 going ex on Aug 16, 2024
Aug 16, 2024
Aug 26, 2024
Aug 16, 2024
Jan 31, 2024
NVO.NB Interim Cash Dividend of gross USD 0.929335 paid on Apr 02, 2024 going ex on Mar 22, 2024
Mar 25, 2024
Apr 02, 2024
Mar 22, 2024
Aug 10, 2023
NVO.NB Final Cash Dividend of gross USD 0.876339 paid on Aug 29, 2023 going ex on Aug 18, 2023
Aug 21, 2023
Aug 29, 2023
Aug 18, 2023
Feb 02, 2023
NVO.NB Interim Cash Dividend of gross USD 1.180581 paid on Apr 04, 2023 going ex on Mar 24, 2023
Mar 27, 2023
Apr 04, 2023
Mar 24, 2023
Aug 04, 2022
NVO.NB Final Cash Dividend of gross USD 0.577745 paid on Aug 23, 2022 going ex on Aug 12, 2022
Aug 15, 2022
Aug 23, 2022
Aug 12, 2022
Mar 02, 2022
NVO.NB Interim Cash Dividend of gross USD 1.022424 paid on Apr 05, 2022 going ex on Mar 25, 2022
Mar 28, 2022
Apr 05, 2022
Mar 25, 2022
Aug 05, 2021
NVO.NB Final Cash Dividend of gross USD 0.550289 paid on Aug 25, 2021 going ex on Aug 16, 2021
Aug 17, 2021
Aug 25, 2021
Aug 16, 2021
Feb 22, 2021
NVO.NB Interim Cash Dividend of gross USD 0.922122 paid on Apr 07, 2021 going ex on Mar 26, 2021
Mar 29, 2021
Apr 07, 2021
Mar 26, 2021
Aug 06, 2020
NVO.NB Final Cash Dividend of gross USD 0.517777 paid on Aug 25, 2020 going ex on Aug 14, 2020
Aug 17, 2020
Aug 25, 2020
Aug 14, 2020
Feb 06, 2020
NVO.NB Interim Cash Dividend of gross USD 0.782605 paid on Apr 07, 2020 going ex on Mar 27, 2020
Mar 30, 2020
Apr 07, 2020
Mar 27, 2020
Aktien-Split
Datum
Art
Verhältnis
Aug 14, 2023
Split
1>2
Datum
Art
Verhältnis
Aug 14, 2023
Split
1>2